DNA Systems, Inc.
CIK:0001441551|SEC Filings
|
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
|
3 Months Ended | 6 Months Ended | 48 Months Ended | ||
|---|---|---|---|---|---|
|
Oct. 31, 2011
|
Oct. 31, 2010
|
Oct. 31, 2011
|
Oct. 31, 2010
|
Oct. 31, 2011
|
|
| Revenue | $ 6,407 | ||||
| Expenses: | |||||
| Formation expenses | 513 | ||||
| General and administrative | 3,530 | 4,500 | 5,616 | 6,708 | 154,728 |
| Loss from operations | (3,530) | (4,500) | (5,616) | (6,708) | (148,834) |
| Loss before income taxes | (3,530) | (4,500) | (5,616) | (6,708) | (148,834) |
| Net Loss | (3,530) | (4,500) | (5,616) | (6,708) | (148,834) |
| Other comprehensive income: | |||||
| Foreign currency translation gain | (155) | 111 | (45) | 128 | (343) |
| COMPREHENSIVE LOSS | $ (3,685) | $ (4,389) | $ (5,661) | $ (6,580) | $ (149,177) |
| Net loss per share basic and diluted | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ (0.02) |
| Weighted average common stock outstanding basic and diluted | 8,700,000 | 8,582,609 | 8,700,000 | 8,541,304 | 8,305,926 |
|
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
|
3 Months Ended | 6 Months Ended | 48 Months Ended | ||
|---|---|---|---|---|---|
|
Oct. 31, 2011
|
Oct. 31, 2010
|
Oct. 31, 2011
|
Oct. 31, 2010
|
Oct. 31, 2011
|
|
| Net Loss | $ (3,530) | $ (4,500) | $ (5,616) | $ (6,708) | $ (148,834) |
| Changes in liabilitiy: | |||||
| Other payables | (12,019) | ||||
| Changes in accrued audit fee | 1,187 | (2,055) | 2,439 | (2,056) | 8,296 |
| Net cash used in operating activities | (2,343) | (18,574) | (3,177) | (8,764) | (140,538) |
| Cash flows from financing activities: | |||||
| Proceeds from issuance of common stock | 100,000 | 100,000 | 108,500 | ||
| Advances from/(repayment to) a stockholder | 2,424 | (85,115) | 3,036 | (92,032) | 33,261 |
| Net cash provided by/(used in) financing activities | 2,424 | 14,885 | 3,036 | 7,968 | 141,761 |
| Effect of exchange rate changes in cash and cash equivalents | (155) | 111 | (45) | 128 | (343) |
| Net Change in Cash and Cash Equivalents | (74) | (3,578) | (186) | (668) | 880 |
| Initial Cash and Cash Equivalents | 954 | 4,762 | 1,066 | 1,852 | |
| Final Cash and Cash Equivalents | $ 880 | $ 1,184 | $ 880 | $ 1,184 | $ 880 |
|
CONSOLIDATED BALANCE SHEETS (USD $)
|
Oct. 31, 2011
|
Apr. 30, 2011
|
||||||
|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||
| Cash and cash equivalents | $ 880 | $ 1,066 | ||||||
| Total assets | 880 | 1,066 | ||||||
| Current liabilities: | ||||||||
| Accrued audit fee | 8,296 | 5,857 | ||||||
| Amount due to a stockholder | 33,261 | 30,225 | ||||||
| Total liabilities | 41,557 | 36,082 | ||||||
| Stockholders' equity: | ||||||||
| Common stock | 8,700 | [1] | 8,700 | [2] | ||||
| Additional paid-in capital | 99,800 | 99,800 | ||||||
| Accumulated deficit during the development stage | (148,834) | (143,218) | ||||||
| Accumulated other comprehensive income | (343) | (298) | ||||||
| Total stockholders' equity | (40,677) | (35,016) | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 880 | $ 1,066 | ||||||
|
||||||||